Alexion Pharmaceuticals Bruttomarge
Was ist das Bruttomarge von Alexion Pharmaceuticals?
Bruttomarge von Alexion Pharmaceuticals Inc. ist 90.94%
Was ist die Definition von Bruttomarge?
Die Bruttomarge ist die Differenz zwischen Umsatz und Kosten der verkauften Waren, dividiert durch den Umsatz und in Prozent ausgedrückt.
Gross margin is a type of profit margin, specifically a form of profit divided by net revenue. It is generally calculated as the selling price of an item, minus the cost of goods sold (production or acquisition costs, not including indirect fixed costs like rent, or administrative costs). The purpose of margins is to give a description of the gross profit.
Bruttomarge von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Alexion Pharmaceuticals
Was macht Alexion Pharmaceuticals?
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.
Unternehmen mit bruttomarge ähnlich Alexion Pharmaceuticals
- Tarsus Pharmaceuticals hat Bruttomarge von 90.87%
- Country Club Hospitality & Holidays hat Bruttomarge von 90.88%
- Alexion Pharmaceuticals hat Bruttomarge von 90.88%
- ALBIS Leasing AG hat Bruttomarge von 90.89%
- iCar Asia hat Bruttomarge von 90.90%
- Onxeo SA hat Bruttomarge von 90.94%
- Alexion Pharmaceuticals hat Bruttomarge von 90.94%
- Covivio Hotels Societe anonyme hat Bruttomarge von 90.95%
- Ocular Therapeutix Inc hat Bruttomarge von 90.96%
- New Century Hong Kong hat Bruttomarge von 90.98%
- Triple Flag Precious Metals hat Bruttomarge von 91.03%
- Joint Corp hat Bruttomarge von 91.04%
- Centurion Minerals hat Bruttomarge von 91.07%